Anupam Rama of JP Morgan, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Decreased Target from $20 to $19 on, Nov 18th, 2022.
Anupam has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Anupam's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Anupam
- Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $23 on, Wednesday, August 24th, 2022
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $30 on, Tuesday, July 26th, 2022
